Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF), a plant-based extraction company specializing in cannabis, hemp and mushroom products, has released the timetable and milestones for a proprietary study. The study is designed to evaluate the formulation, manufacturing and clinical bioavailability of psilocybin-based, rapid-onset active treatments for a nasal gel as well as oral tablets and capsules that will be used as an investigational product. PULL anticipates that the study will be conducted by Dr. Alexander MacGregor at the Toronto Institute of Pharmaceutical Technology (“TIPT”); MacGregor is a scientific advisor for Pure Extracts. During the study, the company will be evaluating several key elements, including the sourcing and procurement of medicinal ingredients, excipients and packaging materials; raw material testing; the formulation and manufacturing process development and stability testing; clinical batch manufacturing; quality-control release testing; and shipping of clinical batches to CRO (“CRO”). “We are excited about the R&D progress we are going to make with TIPT over the next six to eight months while waiting to receive our Dealer’s License from Health Canada,” said Pure Extracts CEO Ben Nikolaevsky in the press release. “We will be well prepared for our move into the controlled substances world of psychedelics and will have advanced knowledge regarding psilocybin and its associated novel delivery mechanisms.”
To view the full press release, visit https://ibn.fm/dR030
About Pure Extracts Technologies Corp.
Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of world-famous Whistler, British Columbia. The bespoke facility has been constructed to European Union GMP standards aiming towards export sales of products and formulations, including those currently restricted in Canada, into European jurisdictions where they are legally available. On Sept. 25, 2020, Pure Extracts was granted its Standard Processing License by Health Canada under the Cannabis Act. In addition, the company’s stock began trading on the Canadian Securities Exchange (“CSE”) on Nov. 5, 2020. For more information about the company, please visit www.PureExtractsCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.